Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SCYNEXIS, Inc. SCYX

Healthcare  —  Drug Manufacturers Specialty & Generic
4.39 (0.06) (1.35%) as of 25 Sep
Market cap
$45.0M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

SCYNEXIS, Inc. (SCYX) Business Profile

Updated before January 2025

Company Overview

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company dedicated to the development and commercialization of innovative therapies for difficult-to-treat and life-threatening infections. Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS has established itself as a leader in antifungal research and development. The company was initially spun out of Aventis (now Sanofi) and has since focused on leveraging its expertise in antifungal drug discovery to address unmet medical needs. SCYNEXIS is led by a team of seasoned professionals, including Marco Taglietti, M.D., who serves as the President and Chief Executive Officer. Dr. Taglietti brings decades of experience in pharmaceutical development and commercialization, which has been instrumental in driving the company’s strategic vision.

Core Business Segments

SCYNEXIS operates primarily in the field of antifungal therapeutics, with a focus on developing novel treatments for fungal infections that are resistant to existing therapies. The company’s core business segments include:

1. Antifungal Therapies

Ibrexafungerp (BREXAFEMME®)

SCYNEXIS’s flagship product is Ibrexafungerp, marketed under the brand name BREXAFEMME®. It is the first and only FDA-approved oral antifungal in a novel class of glucan synthase inhibitors. BREXAFEMME® is indicated for the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent VVC. This groundbreaking therapy addresses a significant unmet need for patients who require effective and convenient antifungal treatments.

Pipeline Products

SCYNEXIS is also advancing the development of Ibrexafungerp for other indications, including invasive fungal infections such as candidemia and invasive aspergillosis. These conditions are often life-threatening and represent a critical area of focus for the company.

2. Research and Development (R&D)

SCYNEXIS invests heavily in R&D to expand its antifungal portfolio. The company is exploring the potential of Ibrexafungerp in combination therapies and is conducting clinical trials to evaluate its efficacy against multidrug-resistant fungal pathogens.

Business Model

SCYNEXIS’s business model is centered on the development, approval, and commercialization of innovative antifungal therapies. The company generates revenue through product sales, licensing agreements, and strategic partnerships. Key aspects of its business model include:

  • Product Commercialization: SCYNEXIS markets BREXAFEMME® directly in the United States and collaborates with international partners for global distribution.
  • Licensing and Partnerships: The company has entered into licensing agreements with pharmaceutical companies to expand the reach of its products. For example, SCYNEXIS has partnered with GSK for the global development and commercialization of Ibrexafungerp.
  • Clinical Development: SCYNEXIS invests in clinical trials to expand the indications for its products, thereby increasing their market potential.

Strategic Direction

SCYNEXIS is committed to addressing the growing threat of antifungal resistance and improving patient outcomes. The company’s strategic priorities include:

  • Expanding Indications for Ibrexafungerp: SCYNEXIS is conducting Phase 3 clinical trials to evaluate Ibrexafungerp for the treatment of invasive fungal infections, which could significantly broaden its market.
  • Global Expansion: Through partnerships and licensing agreements, SCYNEXIS aims to make its therapies available to patients worldwide.
  • Sustainability Goals: The company is focused on sustainable manufacturing practices and minimizing its environmental impact.
  • Innovation in Antifungal Therapies: SCYNEXIS continues to invest in R&D to develop next-generation antifungal treatments.

Competitive Landscape

SCYNEXIS operates in a competitive market that includes both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Pfizer Inc.: A major player in the antifungal market with products like Diflucan® (fluconazole) and Vfend® (voriconazole).
  • Merck & Co., Inc.: Known for its antifungal drug Cancidas® (caspofungin).
  • Cidara Therapeutics: A biotech company focused on developing long-acting antifungal therapies.
  • Amplyx Pharmaceuticals: Specializes in treatments for invasive fungal infections.

SCYNEXIS differentiates itself through its novel approach to antifungal therapy and its focus on addressing unmet medical needs.

Risk Factors

SCYNEXIS faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: The company relies heavily on the success of Ibrexafungerp, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: The development and approval of new drugs are subject to stringent regulatory requirements, which can delay product launches.
  • Supply Chain Disruptions: SCYNEXIS depends on third-party manufacturers for the production of its therapies, making it susceptible to supply chain issues.
  • Financial Risks: As a clinical-stage biotech company, SCYNEXIS may face challenges in securing funding for its R&D programs and operational expenses.

Recent Developments

SCYNEXIS has made significant progress in recent years, including:

  • Partnership with GSK: In 2023, SCYNEXIS entered into a licensing agreement with GSK for the global development and commercialization of Ibrexafungerp. This partnership provides SCYNEXIS with additional resources to expand its market reach.
  • FDA Approvals: The company received FDA approval for BREXAFEMME® for the treatment and prevention of VVC, marking a major milestone in its commercialization efforts.
  • Clinical Trials: SCYNEXIS is advancing its clinical pipeline with ongoing trials for Ibrexafungerp in invasive fungal infections.

Investment Considerations

Investors considering SCYNEXIS should weigh the following factors:

Strengths

  • Innovative Product Portfolio: SCYNEXIS’s novel antifungal therapies address significant unmet medical needs.
  • Strong Partnerships: Collaborations with companies like GSK enhance SCYNEXIS’s market potential.
  • Growth Opportunities: Expanding indications for Ibrexafungerp and global distribution agreements provide avenues for revenue growth.

Risks

  • Market Dependence: Heavy reliance on a single product increases financial risk.
  • Regulatory and Clinical Risks: Delays in clinical trials or regulatory approvals could impact the company’s growth.
  • Competition: SCYNEXIS faces competition from established pharmaceutical companies and emerging biotech firms.

Conclusion

SCYNEXIS, Inc. is a pioneering biotechnology company with a strong focus on antifungal therapies. Its innovative product portfolio, strategic partnerships, and commitment to addressing unmet medical needs position it as a leader in the field. While the company faces challenges such as market dependence and regulatory risks, its growth potential and recent developments make it an attractive investment opportunity. With a clear strategic direction and a robust pipeline, SCYNEXIS is well-positioned for future success in the global healthcare market.